Head to head
Protagonist Therapeutics vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: PTGX · VRTX
PTGX
Protagonist Therapeutics
121.40-2.11%
1-year price shape — +44% over the period
Quant Rating C · 84/100
vs
VRTX
Vertex Pharmaceuticals
515.02-1.08%
1-year price shape — +22% over the period
Quant Rating C · 68/100
1-year performance, rebased to 100
Protagonist Therapeutics edges it on the scoreable measures. Protagonist Therapeutics has the highest Quant Rating (84); Protagonist Therapeutics has done best over the past year (+44%); Protagonist Therapeutics trades cheapest on trailing earnings.
| PTGX | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 121.40 | 515.02 |
| Change today | -2.11% | -1.08% |
| 1-year return | +44.2% | +22.0% |
| Market cap | $7.92B | $130.58B |
| 52-week range | 77.00 – 160.81 | 412.27 – 568.67 |
| Valuation | ||
| P/E (TTM) | 25.67 | 33.14 |
| P/E percentile, own 5-yr range | 78th | 99th |
| P/B | 7.30 | 6.25 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -2.05 | 15.32 |
| Net profit (TTM) | $-133.80M | $3.88B |
| Revenue (TTM) | $551.69M | $12.95B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +5723.6% | +11.8% |
| Gross margin | -- | 85.5% |
| Operating margin | 58.6% | 33.1% |
| Net margin | 62.0% | 30.7% |
| Free cash flow (TTM) | $109.15M | $3.20B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 122.4% | 96.8% |
| Insider activity (12mo) | 17 buy / 33 sell | 28 buy / 22 sell |
| Short interest (% of float) | 15.8% | 1.9% |
| Analyst consensus | 100% buy (13) | 95% buy / 5% hold (21) |
| Analyst price target | $180 (+48%) | $624 (+21%) |
| StockVane view | ||
| StockVane Quant Rating | C (84) | C (68) |
| Company | ||
| Employees | 132 | 6,400 |
| Founded | 2006 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.